{"pmid":32467314,"title":"Cluster of chalazia in nurses using eye protection while caring for critically ill patients with COVID-19 in intensive care.","text":["Cluster of chalazia in nurses using eye protection while caring for critically ill patients with COVID-19 in intensive care.","Occup Environ Med","Megarbane, Bruno","Tadayoni, Ramin","32467314"],"journal":"Occup Environ Med","authors":["Megarbane, Bruno","Tadayoni, Ramin"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467314","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1136/oemed-2020-106677","keywords":["ppe","hygiene / occupational hygiene","toxicology"],"topics":["Prevention"],"weight":1,"_version_":1668167109941657601,"score":9.490897,"similar":[{"pmid":32398850,"title":"Care for critically Ill patients with COVID-19: don't forget the eyes.","text":["Care for critically Ill patients with COVID-19: don't forget the eyes.","Eye (Lond)","Ting, Darren Shu Jeng","Deshmukh, Rashmi","Said, Dalia G","Dua, Harminder S","32398850"],"journal":"Eye (Lond)","authors":["Ting, Darren Shu Jeng","Deshmukh, Rashmi","Said, Dalia G","Dua, Harminder S"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32398850","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41433-020-0959-0","topics":["Prevention"],"weight":1,"_version_":1666714494786600961,"score":60.30717},{"pmid":32344460,"title":"The potential for COVID-19 to contribute to compassion fatigue in critical care nurses.","text":["The potential for COVID-19 to contribute to compassion fatigue in critical care nurses.","As of April 2020, more than 2 million people worldwide had tested positive for COVID-19, and more than 200,000 deaths are attributed to this virus. It is estimated that around 15% of patients diagnosed with COVID-19 will develop severe health complications, and around 5- 10% will require intensive level care due to the seriousness of the symptoms and the high mortality risk (3-5%)( Baud et al., 2020; Murthy, Gomersall, & Fowler, 2020). At the time of writing, COVID-19 has caused the need for hospitalisation of thousands of people due to the serious pneumonia type symptoms that result in extreme breathing difficulty.","J Clin Nurs","Alharbi, Jalal","Jackson, Debra","Usher, Kim","32344460"],"abstract":["As of April 2020, more than 2 million people worldwide had tested positive for COVID-19, and more than 200,000 deaths are attributed to this virus. It is estimated that around 15% of patients diagnosed with COVID-19 will develop severe health complications, and around 5- 10% will require intensive level care due to the seriousness of the symptoms and the high mortality risk (3-5%)( Baud et al., 2020; Murthy, Gomersall, & Fowler, 2020). At the time of writing, COVID-19 has caused the need for hospitalisation of thousands of people due to the serious pneumonia type symptoms that result in extreme breathing difficulty."],"journal":"J Clin Nurs","authors":["Alharbi, Jalal","Jackson, Debra","Usher, Kim"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344460","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jocn.15314","locations":["Murthy"],"topics":["Prevention"],"weight":1,"_version_":1666138495836487682,"score":59.543983},{"pmid":32281481,"pmcid":"PMC7157945","title":"Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.","text":["Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.","As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested in vivo and in vitro for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests.","J Toxicol Environ Health B Crit Rev","Pereira, Boscolli Barbosa","32281481"],"abstract":["As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested in vivo and in vitro for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests."],"journal":"J Toxicol Environ Health B Crit Rev","authors":["Pereira, Boscolli Barbosa"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281481","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1080/10937404.2020.1752340","keywords":["toxicology","health care","public health","retinopathy","screening"],"locations":["vivo"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138491423031296,"score":52.579372},{"pmid":32395037,"title":"Protecting yourself and your patients from COVID-19 in eye care.","text":["Protecting yourself and your patients from COVID-19 in eye care.","Community Eye Health","Hu, Victor H","Watts, Elanor","Burton, Matthew","Kyari, Fatima","Mathenge, Ciku","Heidary, Fatemeh","Hoffman, Jeremy","Wolvaardt, Elmien","32395037"],"journal":"Community Eye Health","authors":["Hu, Victor H","Watts, Elanor","Burton, Matthew","Kyari, Fatima","Mathenge, Ciku","Heidary, Fatemeh","Hoffman, Jeremy","Wolvaardt, Elmien"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395037","source":"PubMed","week":"202020|May 11 - May 17","topics":["Prevention"],"weight":1,"_version_":1666627828005732352,"score":52.494305},{"pmid":32356251,"title":"Medical Toxicology and COVID-19: Our Role in a Pandemic.","text":["Medical Toxicology and COVID-19: Our Role in a Pandemic.","J Med Toxicol","Neumann, Natalie R","Chai, Peter R","Wood, David M","Greller, Howard A","Mycyk, Mark B","32356251"],"journal":"J Med Toxicol","authors":["Neumann, Natalie R","Chai, Peter R","Wood, David M","Greller, Howard A","Mycyk, Mark B"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356251","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1007/s13181-020-00778-4","keywords":["covid-19","drug-related side effects and adverse reactions","pandemics","poisoning","toxicology"],"topics":["Prevention"],"weight":1,"_version_":1666138495175884802,"score":50.741882}]}